 VANCOUVER, British Columbia, May 13, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company NASDAQ:INM, a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol CBN, today reported financial results for the third quarter of fiscal year 2021 3Q21 which ended March 31, 2021. 